查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球女性尿失禁治疗设备市场-2022-2029
市场调查报告书
商品编码
1140744

全球女性尿失禁治疗设备市场-2022-2029

Global Female Urinary Incontinence Treatment Device Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 170 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

孕妇尿失禁患病率上升

根据 BMC 于 2022 年 1 月发布的一项研究，有 1243 名女性参加了研究。妊娠期尿失禁发生率为52.0%。大多数女性患有轻度或中度尿失禁。通过多元逻辑回归确定了五个风险因素。孕前尿失禁是最强的预测因子，其次是阴道分娩史、咖啡消费、儿童尿崩症和尿路感染史。尿失禁对怀孕期间与健康相关的生活质量有显着影响。只有 14.8% 的孕妇因排尿症状寻求专业帮助。与尿失禁显着相关的因素包括年龄组、胎龄、分娩次数、尿失禁史、便秘、最后一次分娩方式、尿路感染史和妊娠期肥胖。

此外，在预测期内，低价自有品牌产品的流行正在推动市场增长。由于女性压力性尿失禁治疗市场的产品种类繁多，小企业正在引起兴趣并以低价销售他们的产品。预计自有品牌的价格渗透率显着降低将降低女性尿失禁压力设备的平均总体价格。阻碍对昂贵产品的需求可能会阻碍全球女性压力性尿失禁设备市场的增长。

地理渗透。

北美是预测期内的主要地区。

该研究按地区分析了全球市场的女性尿失禁设备市场，包括北美、欧洲、亚太地区、南美、中东和非洲。

北美在 2021 年将主导全球女性尿失禁设备市场。在北美，预计美国在预测期内将出现大幅增长。在美国，女性尿失禁治疗设备的潜在增长是由孕妇尿失禁、糖尿病引起的压力性尿失禁、妇科疾病和绝经后妇女尿失禁的患病率上升推动的。

由于意识的提高、对医疗保健的投资增加以提供负担得起的最佳设施以及社会经济发展，预计亚太市场将在预测期内显着扩大。在中国，随着女性吸烟人数的增加，市场有望增长。新兴国家的主要参与者增加投资预计将提振市场。由于认知度低、可支配收入低和医疗设施有限，预计中东和非洲市场将适度扩张。

竞争格局

Karl Storz、Johnson &Johnson、Coloplast、Boston Scientific、Teleflex、American Medical Solutions等是女性尿失禁设备市场的主要参与者，为全球市场的增长做出了贡献。领先公司正在为女性尿失禁治疗设备市场的全球增长采取新产品引进和扩张战略。2022年5月，以女性为主导的公司联想将推进女性盆底疾病数字疗法的开发，让1000名Leva处方医生能够获得女性尿失禁的一线治疗。Leva 是一种易于使用的骨盆健康管理系统，可减少尿失禁 (UI) 的症状，包括膀胱过度活动症。Leva 在医疗保健专业人员中的迅速采用反映了他们希望改善 UI 保守治疗的可及性。这种情况影响了美国 62% 的成年女性，并且随着时间的推移往往会进展和恶化。2021 年 12 月，Caldera Medical 宣布 FDA 批准新的 Desara TVez 用于压力性尿失禁。该公司扩大了其针对患有压力性尿失禁的女性的治疗选择组合。Caldera Medical 与数十位领先的外科医生合作，以增强易用性和患者安全性将 Desara TVez 带入生活。2022 年 2 月，库克的医疗业务被The Cooper Companies 收购，以在 MedSurg 部门内推广库克的整个生殖健康业务。The Cooper Companies 专注于女性健康和生殖解决方案，为 ART 之旅的每一步提供创新产品和服务。一些主要参与者正在遵循合併和合作战略来扩展业务。例如，2020 年 10 月，Johnson & Johnson以约 65 亿美元的价格完成了对 Momenta Pharmaceuticals 的收购。Momenta 在开发罕见病药物方面有着令人印象深刻的记录。一起拓展您的业务。

COVID-19 的影响将对全球女性尿失禁治疗设备市场产生负面影响。

COVID-19 的爆发对全球女性尿失禁治疗设备市场的增长产生了负面影响。对医院服务的限制影响了尿失禁患者的专业检查和手术治疗。因此，COVID-19大流行对2020年女性尿失禁治疗设备的市场价值产生了负面影响。

全球女性尿失禁治疗设备市场报告提供大约 61 个市场数据表、50 个数字和 170 页的结构。

目录

第一章 调查方法和范围

  • 调查方法
  • 调查目的和范围

第二章市场定义和概述

第三章执行摘要

  • 按产品类型划分的市场细分
  • 按使用材料划分的市场细分
  • 最终用户的市场细分
  • 区域市场细分

第四章市场动态

  • 市场影响因素
    • 促进者
      • 孕妇尿失禁患病率上升
      • 其他与压力相关的尿失禁增加，如糖尿病、妇科疾病和绝经后妇女的尿失禁
      • 子宫切除术增加
      • 女性肥胖增加
    • 抑製剂
      • 女性对尿失禁治疗缺乏认识
    • 影响分析

第五章行业分析

  • 波特五力分析
  • 供应链分析
  • 价值链分析
  • PEST分析
  • 定价分析
  • 监管分析
  • 保险报销分析
  • 未满足的需求
  • 专利趋势

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 中的价格动态
  • 供需谱
  • 大流行期间与市场相关的政府努力
  • 製造商的战略举措
  • 概括

第 7 章按产品类型

  • 尿道装置
  • 阴道内留置装置

第 8 章 按所用材料

  • 发泡聚氨酯
  • 硅酮

第 9 章最终用户

  • 医院
  • 专科诊所
  • 门诊手术中心

第10章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 亚太其他地区
  • 中东/非洲

第 11 章 竞争格局

  • 竞争情景
  • 市场/份额分析
  • 併购分析

第十二章公司简介

  • Bard Medical
    • 公司简介
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Karl Storz
  • Johnson & Johnson
  • Coloplast
  • Boston Scientific
  • Teleflex
  • AMERICAN MEDICAL SOLUTIONS
  • Ethicon, Inc.
  • Caldera Medical Inc
  • COOK MEDICAL（*LIST NOT EXHAUSTIVE*）

第 13 章 重要注意事项

第 14 章 数据管理

简介目录
Product Code: DMMD3131

Market Overview

Female Urinary Incontinence Treatment Device Market was valued at USD YY million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of YY % during the forecast period (2022-2029).

Female urinary incontinence has been diagnosed as a condition that causes involuntary urination. Urinary incontinence or stress urinary incontinence typically occurs during physical activities, such as sneezing, coughing, running, or even during weightlifting, as these activities exert pressure on the urinary bladder. Urinary urge and stress incontinence are different, as the former occurs when the bladder muscles are contracted. Urinary stress incontinence affects women more than men and is mostly due to weak muscle sphincter, which can lead to social isolation. Female urinary incontinence is of two types: the first is urethral hypermobility and the second is due to an inherent sphincter deficiency. In the case of urethra hypermobility, increased abdominal pressure changes the position of the urethra. On the other hand, in the inherent sphincter of the deficiency, the sphincter has lost its ability to seal the deficiency of the intestinal sphincter. The major factors propelling the growth of the female urinary incontinence treatment device market are the rising prevalence of urinary incontinence in pregnant women, stress urinary incontinence due to diabetes, gynecology disorders, and urinary incontinence in postmenopausal women and rising cases of hysterectomy. Moreover, the rising incidence of obesity in the female population is the major factor expected to deliver significant growth to the market in the upcoming period.

Market Dynamics: Rising prevalence of urinary incontinence in pregnant women

According to the research published by BMC in January 2022, 1243 women were enrolled in the study. The prevalence of urinary incontinence during pregnancy was 52.0%. Most women suffer from mild or moderate incontinence. Multiple logistic regressions identified five risk factors. Urinary incontinence before pregnancy was the strongest predictor of incontinence, followed by the history of vaginal birth, coffee consumption, childhood enuresis and history of urinary tract infection. Urinary incontinence had a significant impact on health-related quality of life during pregnancy. Only 14.8% of pregnant women sought professional help for urinary symptoms. Factors significantly associated with urinary incontinence included age group, gestational age, parity, prior urinary incontinence, constipation, last childbirth mode of delivery, previous urinary tract infection, and body mass index during pregnancy.

Moreover, an increase in the penetration of private-label brands at much lower prices drives market growth in the forecast period. Due to the presence of a wide range of products on the market for female stress urinary incontinence treatment devices, small players are gaining interest and selling their products at lower prices. An increase in the penetration of private-label brands at much lower prices is expected to reduce the average overall price of female urinary incontinence stress treatment devices. It is likely to constrain the growth of the global market for female stress urinary incontinence treatment devices, as it is likely to hinder demand for expensive products.

Market Segmentation: The internal vaginal device segment is projected to be the dominant segment in the market during the forecast period.

Based on the product type, the female urinary incontinence treatment device market has been classified into urethral devices and internal vaginal devices.

The internal vaginal devices segment can be further categorized into traditional devices and custom-made devices. Urinary stress incontinence is significantly more common in women than in men. Female urinary incontinence treatment device occurs when pelvic floor muscles or urinary sphincter are likely to lose strength, either due to women's childbirth or men's prostate surgery. Thus, due to such factors, the internal vaginal device is expected to hold a dominant position in the market.

The female urinary incontinence treatment device is segmented based on end-user, which includes hospitals, speciality clinics, and ambulatory surgical centers.

The hospital pharmacies segment is expected to hold a significant market share in the female urinary incontinence treatment device market. Hospital in the end-user segment is expected to have a significant share of the global market for urinary incontinence devices due to the large patient population treated in hospitals suffering from urinary incontinence. Moreover, hospitals are expected to grow with the highest CAGR in the forthcoming period with the rise in technological advancement in the industry.

Furthermore, the female urinary incontinence treatment device is segmented on the basis of material used, which includes polyurethane foam and silicone. Polyurethane foam is the dominating segment along with projected to grow with the highest CAGR in the forthcoming period.

Geographical Penetration: North America is the dominating region during the forecast period.

Based on geography, the study analyzes the female urinary incontinence treatment device market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

North America is holding a dominant position in the global female urinary incontinence treatment device market in 2021. In North America, the U.S. is expected to represent considerable growth during the forecast period. In the U.S., the female urinary incontinence treatment device is expected to have potential growth due to the rising prevalence of urinary incontinence in pregnant women and stress urinary incontinence due to diabetes, gynecology disorders, and urinary incontinence in postmenopausal women.

The Asia-Pacific market is projected to expand significantly during the forecast period due to increased awareness, increased investment in health care to provide optimum facilities at affordable cost, and socio-economic development. The increase in the number of women smoking in China is expected to boost the market. Increased investment by prominent players in developing countries is expected to boost the market. The Middle East & Africa market is projected to expand slowly due to a lack of awareness, low disposable income, and limited healthcare facilities.

Competitive Landscape:

The key female urinary incontinence treatment device market players contributing to the global market's growth include Karl Storz, Johnson & Johnson, Coloplast, Boston Scientific, Teleflex, and American Medical Solutions, among others. The major players are adopting new product launches and expansion strategies for global growth in the female urinary incontinence treatment device market. In May 2022, Renovia, a women-led company, advances the development of digital therapeutics for female pelvic floor disorders access to first-line treatment for female urinary incontinence with 1,000 leva prescribers. Leva is a pelvic health system that is easy to use and that help woman decreases the symptoms of urinary incontinence (UI) symptoms, including overactive bladder. Leva's accelerated adoption among healthcare providers reflects their desire to improve access to conservative treatment for UI. This condition affects 62% of adult women in the U.S. and tends to progress and worsen over time. In December 2021, Caldera Medical announced FDA approval for the New Desara TVez for Stress Urinary Incontinence. The company expands its product portfolio of treatment options for women suffering from Stress Urinary Incontinence. Caldera Medical collaborated with dozens of leading surgeons to bring enhanced ease of use and patient safety to life in the form of Desara TVez. In February 2022, Cook's medical business was acquired by CooperCompanies to sell the entirety of Cook's Reproductive Health business within the MedSurg division. Cooper Companies focuses on women's health and fertility solutions, providing innovative products and services for every step in the ART journey. Some key players follow merger and collaboration strategies to expand their business. For instance, in October 2020, Johnson & Johnson completed the acquisition of Momenta Pharmaceuticals, Inc. for approximately $6.5 billion. Momenta has made excellent progress in developing its medicines for rare diseases. Together they expand their business.

COVID-19 Impact: Negative impact on the global female urinary incontinence treatment device market.

The outbreak of COVID-19 has negatively impacted the growth of the female urinary incontinence treatment device market globally. Restrictions on hospital services have affected the specialized investigation and surgical management of patients with urinary incontinence. Therefore, the COVID-19 pandemic had a negative impact on the market value of the female urinary incontinence treatment device market in 2020.

The global female urinary incontinence treatment device market report would provide an access to approximately 61 market data tables, 50 figures and 170 pages

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Product Type
  • 3.2. Market Snippet by Material used
  • 3.3. Market Snippet by End-user
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising prevalence of urinary incontinence in pregnant women
      • 4.1.1.2. Stress urinary incontinence due to diabetes, gynecology disorders, and urinary incontinence in postmenopausal women
      • 4.1.1.3. Rising cases of hysterectomy
      • 4.1.1.4. Rising incidence of obesity in the female population
    • 4.1.2. Restraint
      • 4.1.2.1. Lack of awareness among women regarding urinary incontinence treatment
    • 4.1.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Value Chain Analysis
  • 5.4. PEST Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs
  • 5.9. Patent Trends

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
  • 7.3. Market Attractiveness Index, By Product Type Segment
    • 7.3.1. Urethral devices
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Internal vaginal devices

8. By Material used

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Material used Segment
  • 8.3. Market Attractiveness Index, By Material Segment
    • 8.3.1. Polyurethane Foam
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Silicone

9. By End user

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user Segment
  • 9.3. Market Attractiveness Index, By End user Segment
    • 9.3.1. Hospitals
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Specialty clinics
    • 9.3.3. Ambulatory surgical centers

10. By Region

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Material used
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. U.S.
      • 10.4.6.2. Canada
      • 10.4.6.3. Mexico
  • 10.5. Europe
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Material used
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. Germany
      • 10.5.6.2. U.K.
      • 10.5.6.3. France
      • 10.5.6.4. Italy
      • 10.5.6.5. Spain
      • 10.5.6.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Material used
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.6.1. Brazil
      • 10.6.6.2. Argentina
      • 10.6.6.3. Rest of South America
  • 10.7. Asia Pacific
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Material used
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.7.6.1. China
      • 10.7.6.2. India
      • 10.7.6.3. Japan
      • 10.7.6.4. Australia
      • 10.7.6.5. Rest of Asia Pacific
  • 10.8. Middle East and Africa
    • 10.8.1. Introduction
    • 10.8.2. Key Region-Specific Dynamics
    • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Material used
    • 10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Bard Medical*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Karl Storz
  • 12.3. Johnson & Johnson
  • 12.4. Coloplast
  • 12.5. Boston Scientific
  • 12.6. Teleflex
  • 12.7. AMERICAN MEDICAL SOLUTIONS
  • 12.8. Ethicon, Inc.
  • 12.9. Caldera Medical Inc
  • 12.10. COOK MEDICAL (*LIST NOT EXHAUSTIVE*)

13. Premium Insights

14. DataM Intelligence Analysis

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us